Tarceva Price Will Be In Bounds, OSI Says: Above Iressa, Below Gleevec
Executive Summary
Genentech/OSI will price the EGFR inhibitor Tarceva between AstraZeneca's Iressa and Novartis' Gleevec, OSI CEO Colin Goddard, PhD, said
You may also be interested in...
OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing
OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer
OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing
OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer
Cancer Drugs Will Continue To Command High Prices, Scully Predicts
The transformation in the Medicare market will not prevent cancer drugs from commanding very high prices, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Washington Research Group's annual symposium Nov. 5